001     156721
005     20240229133504.0
024 7 _ |a 10.1038/s41397-020-0174-1
|2 doi
024 7 _ |a pmid:32546699
|2 pmid
024 7 _ |a 1470-269X
|2 ISSN
024 7 _ |a 1473-1150
|2 ISSN
024 7 _ |a altmetric:84105897
|2 altmetric
037 _ _ |a DKFZ-2020-01059
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Guberina, Maja
|0 0000-0003-3218-0539
|b 0
245 _ _ |a ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
260 _ _ |a Basingstoke
|c 2021
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1641905192_13364
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Feb;21(1):37-46
520 _ _ |a Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after definitive concurrent radiochemotherapy is of key importance for the selection for consolidation therapy and for individualized treatment intensification. In this multicenter study we analyzed recurrence-associated single-nucleotide polymorphisms (SNPs) in DNA repair genes in tumor DNA from 132 patients with locally advanced head and neck carcinoma (LadHnSCC). Patients were treated with definitive radiotherapy and simultaneous cisplatin-based chemotherapy at six partner sites of the German Cancer Consortium (DKTK) Radiation Oncology Group from 2005 to 2011. For validation, a group of 20 patients was available. Score selection method using proportional hazard analysis and leave-one-out cross-validation were performed to identify markers associated with outcome. The SNPs rs1799793 and rs13181 were associated with survival and the same SNPs and in addition rs17655 with freedom from loco-regional relapse (ffLRR) in the trainings datasets from all patients. The homozygote major rs1799793 genotype at the ERCC2 gene was associated with better (Hazard ratio (HR): 0.418 (0.234-0.744), p = 0.003) and the homozygote minor rs13181 genotype at ERCC2 with worse survival (HR: 2.074, 95% CI (1.177-3.658), p = 0.017) in comparison to the other genotypes. At the ffLRR endpoint, rs1799793 and rs13181 had comparable prognostic value. The rs1799793 and rs13181 genotypes passed the leave-one-out cross-validation procedure and associated with survival and ffLRR in patients with LadHnSCC treated with definitive radiochemotherapy. While findings were confirmed in a small validation dataset, further validation is underway within a prospective biomarker study of the DKTK.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Sak, Ali
|b 1
700 1 _ |a Pöttgen, Christoph
|b 2
700 1 _ |a Tinhofer-Keilholz, Ingeborg
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Budach, Volker
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Balermpas, Panagiotis
|b 5
700 1 _ |a Von der Grün, Jens
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Rödel, Claus Michael
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Gikka, Eleni
|b 8
700 1 _ |a Grosu, Anca-Ligia
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Abdollahi, Amir
|0 P:(DE-He78)360c5bc2b71a849e35aca747c041dda7
|b 10
|u dkfz
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 11
|u dkfz
700 1 _ |a Belka, Claus
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Pigorsch, Steffi
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Combs, Stephanie
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Mönnich, David
|0 P:(DE-He78)a71604d1adbf3bced939fcfcf2c7ff32
|b 15
700 1 _ |a Zips, Daniel
|0 P:(DE-HGF)0
|b 16
700 1 _ |a De-Colle, Chiara
|b 17
700 1 _ |a Welz, Stefan
|b 18
700 1 _ |a Linge, Annett
|0 P:(DE-He78)81b719227985a27b1b77ed6766094319
|b 19
|u dkfz
700 1 _ |a Lohaus, Fabian
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Baretton, Gustavo
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Gauler, Thomas
|b 22
700 1 _ |a Baumann, Michael
|0 P:(DE-He78)933f7d725ac87378f459623783585a1f
|b 23
|u dkfz
700 1 _ |a Krause, Mechthild
|0 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9
|b 24
|u dkfz
700 1 _ |a Schuler, Martin
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Bankfalvi, Agnes
|b 26
700 1 _ |a Höing, Benedikt
|b 27
700 1 _ |a Lang, Stephan
|b 28
700 1 _ |a Stuschke, Martin
|b 29
773 _ _ |a 10.1038/s41397-020-0174-1
|0 PERI:(DE-600)2051501-7
|n 1
|p 37-46
|t The pharmacogenomics journal
|v 21
|y 2021
|x 1473-1150
909 C O |p VDB
|o oai:inrepo02.dkfz.de:156721
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)360c5bc2b71a849e35aca747c041dda7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)a71604d1adbf3bced939fcfcf2c7ff32
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)81b719227985a27b1b77ed6766094319
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)933f7d725ac87378f459623783585a1f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Addenda
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHARMACOGENOMICS J : 2018
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-01-15
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-01-15
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-15
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-01-15
920 1 _ |0 I:(DE-He78)BE01-20160331
|k BE01
|l DKTK BE zentral
|x 0
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK FR zentral
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK FM zentral
|x 3
920 1 _ |0 I:(DE-He78)E210-20160331
|k E210
|l E210 Translationale Radioonkologie
|x 4
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 5
920 1 _ |0 I:(DE-He78)M010-20160331
|k M010
|l M010 Stiftungsvorstand
|x 6
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK DD zentral
|x 7
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK MU LMU zentral
|x 8
920 1 _ |0 I:(DE-He78)TU01-20160331
|k TU01
|l DKTK TU zentral
|x 9
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK ED ES zentral
|x 10
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)BE01-20160331
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a I:(DE-He78)E210-20160331
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)M010-20160331
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a I:(DE-He78)TU01-20160331
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21